

## References

L-88

1. Friboulet L, Olausson KA, Pignon JP, et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer. *N Engl J Med*. 2013;368(12):1101-1110.
2. Besse B, Olausson KA, Soria JC. ERCC1 and RRM1: Ready for prime time? *J Clin Oncol*. 2013;31(8):1050-1060.
3. Wang TB, Zhang NL and Wang SH et al. Expression of ERCC1 and BRCA1 predict the clinical outcome of non-small cell lung cancer in patients receiving platinum-based chemotherapy. *Genetics and Molecular Research Online Journal*. 2014;13(2):3704-3710.
4. Vinay S, Soria J. ERCC1 as predictor of platinum benefit in non-small-cell lung cancer. *Journal of Clinical Oncology*. 2017;36(4):384-386.
5. Lee S, Falzon M, Blackhall F, Spicer J, et al. Randomized prospective biomarker trial of ERCC1 for comparing platinum and nonplatinum therapy in advanced non-small-cell lung cancer: ERCC1 Trial (ET) *J Clin Onc*. 2017;35(4):402-411.
6. Zhang P, Zue P, Cui S, et al. Different splicing isoforms of ERCC1 affect the expression of its overlapping genes CD3EAP and PPP1R13L, and indicate a potential application in non-small lung cell cancer treatment. *Int J Onc*. 2018;52:2155-2165.